Centessa Pharmaceuticals plc Annual Deferred Income Tax Expense (Benefit) in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Centessa Pharmaceuticals plc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2022 to 2023.
  • Centessa Pharmaceuticals plc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $434K.
  • Centessa Pharmaceuticals plc annual Deferred Income Tax Expense (Benefit) for 2023 was -$26.5M, a 829% decline from 2022.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$26.5M -$23.7M -829% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$2.86M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.